Odisha Receives Investment Commitments Worth ₹7,043 Cr in Pharma & Medtech

Odisha has received investment commitments worth ₹7,043 crore across the pharmaceutical and medical technology sectors, marking a major step in strengthening the state’s position as an emerging healthcare manufacturing hub.

The announcements were made during high-level industry interactions led by the state government, reflecting strong investor confidence in Odisha’s policy framework and industrial infrastructure.

The proposed investments cover pharmaceutical formulations, bulk drugs, medical devices, and allied healthcare manufacturing.

Chief Minister Mohan Charan Majhi said the inflow of investments underscores Odisha’s commitment to building a competitive and innovation-driven industrial ecosystem. “Odisha is focused on creating an enabling environment for pharma and medtech companies through robust infrastructure, transparent governance, and investor-friendly policies.”

Beyond manufacturing scale-up, the investments are expected to drive research, innovation, and technology transfer in the pharma and medtech sectors.

Industries Minister Sampad Chandra Swain highlighted that targeted incentives and sector-specific parks are helping attract long-term investments. “With dedicated industrial clusters and fast-track approvals, Odisha is positioning itself as a preferred destination for pharma and medical device manufacturing.”

He added that the government is working closely with investors to ensure timely project execution and seamless operational support.

Looking ahead, the Odisha government plans to convert these commitments into on-ground projects through continued industry engagement, reinforcing the state’s alignment with national initiatives such as Make in India and Atmanirbhar Bharat, while building a sustainable healthcare manufacturing ecosystem.

Related Posts

CDSCO finds one spurious drug sample in Delhi, 220 NSQs in Aug surveillance

The Central Drugs Standard Control Organisation (CDSCO) found one spurious and 220 not of standard quality (NSQ) drug samples from a batch tested randomly as part of the August drug…

FSDA cancels 16 pharmacy licences, suspends 8, including Pfizer depot

The action follows the department’s investigation into a large-scale unlicenced drug repacking and relabelling racket uncovered at a farmhouse in Bengaluru South district’s Bidadi on August 18. The Karnataka Food…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

CDSCO finds one spurious drug sample in Delhi, 220 NSQs in Aug surveillance

CDSCO finds one spurious drug sample in Delhi, 220 NSQs in Aug surveillance

FSDA cancels 16 pharmacy licences, suspends 8, including Pfizer depot

FSDA cancels 16 pharmacy licences, suspends 8, including Pfizer depot

Excellence of Accredited Hospitals to be judged on how Friendly they are with Patients

Excellence of Accredited Hospitals to be judged on how Friendly they are with Patients

WHO launches new primary health care course to strengthen health systems globally

WHO launches new primary health care course to strengthen health systems globally

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman